RxDoctor Payments Data

Kollagunta Chandrasekhar, MD

Cardiovascular Disease · Winter Haven, FLNPI 1396713491

Payments from drug & device makers

$151,616in general payments, 2019–2025

Across 488 payments — averaging $310.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$58K
  • Amgen$25K
  • Boehringer Ingelheim$16K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15K
  • AstraZeneca$12K
  • Novartis$11K
  • plus $14K from 36 others

What the payments were for

  • Consulting fees$2,71313%
  • Speaking & faculty fees$7,84036%
  • Food & beverage$10,46148%
  • Education$5573%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$151,616 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$547,856
Medicare patients
1,858
Services billed
6,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan607$660,542
EliquisApixaban499$420,842
JardianceEmpagliflozin262$241,477
XareltoRivaroxaban260$233,640
FarxigaDapagliflozin Propanediol158$128,121
Repatha SureclickEvolocumab14$7,466
InpefaSotagliflozin11$7,165
BrilintaTicagrelor12$7,133
Midodrine Hcl37$5,164
Metoprolol Succinate345$3,551
Ranolazine ErRanolazine38$3,268
Dabigatran EtexilateDabigatran Etexilate Mesylate14$2,694
Carvedilol391$2,464
Diltiazem 12hr ErDiltiazem Hcl13$2,309
Amiodarone Hcl81$2,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$11,199$660,542607 claims
PfizerEliquis$427$420,842499 claims
Boehringer IngelheimJardiance$15,721$241,477262 claims
Johnson & JohnsonXarelto$851$233,640260 claims
AstraZenecaFarxiga, Brilinta$12,180$135,254170 claims
Lexicon Pharmaceuticals, Inc.Inpefa$73$7,16511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →